金斯瑞生物科技（1548.HK）完成7712.6万股配售，净筹约23.27亿港元，属9月11日已公告事项的程序性交割

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock
Exchange”) take no responsibility for the contents of this announcement, make no representation as to
its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever
arising from or in reliance upon the whole or any part of the contents of this announcement.
This announcement is for information purposes only and does not constitute an invitation or offer to
acquire, purchase or subscribe for the securities of the Company.
Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly
in the United States or any other jurisdiction where such release or distribution might be unlawful. This
announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for
securities in the United States.
The securities mentioned herein have not been, and will not be, registered under the United States
Securities Act of 1933, as amended (the “U.S. Securities Act”), and may not be offered or sold in the
United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a
transaction not subject to, the registration requirements of the U.S. Securities Act. The Company has no
intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a
public offering of securities in the United States.

Genscript Biotech Corporation
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1548)
COMPLETION OF PLACING OF NEW SHARES UNDER THE GENERAL MANDATE
Joint Overall Coordinators and Joint Placing Agents
(in alphabetical order)

Reference is made to the announcement of Genscript Biotech Corporation (the “Company) dated 11
September 2026 in respect of the placing of new Shares under the general mandate (the “Placing
Announcement”). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as
those defined in the Placing Announcement.
COMPLETION OF THE PLACING
The Board is pleased to announce that all the conditions set out in the Placing Agreement have been fulfilled
and the Completion took place on 15 September 2026 in accordance with the terms and conditions of the
Placing Agreement.

1

A total of 77,126,000 Placing Shares, representing approximately 3.50% of the existing issued share capital
of the Company immediately before completion of the Placing, and approximately 3.38% of the issued share
capital of the Company as enlarged by the allotment and issue of the Placing Shares immediately after
completion of the Placing, have been successfully placed to not less than six Placees at the Placing Price of
HK$30.50 per Share.
To the best of the Directors’ knowledge, information and belief, having made all reasonable enquiries, each
of the Placees and their respective ultimate beneficial owner(s) (where applicable) is an Independent Third
Party. Furthermore, as far as the Company is aware, none of the Placees and their ultimate beneficial owners
will become a substantial shareholder (as defined in the Listing Rules) of the Company as a result of the
Placing.
The gross proceeds to the Company from the Placing are approximately HK$2,352.3 million, and the net
proceeds from the Placing, after deducting the placing commission and other relevant costs and expenses of
the Placing, amounted to approximately HK$2,327.1 million. Please refer to the Placing Announcement for
the details of the intended use of proceeds.
As disclosed in the Placing Announcement, following the Completion, the Company will make filings with
the regulatory authorities in the PRC in accordance with the relevant applicable laws and regulations,
including the CSRC Filings.
EFFECTS ON THE SHAREHOLDING STRUCTURE OF THE COMPANY AS A RESULT OF THE
PLACING
The shareholding structure of the Company (i) immediately before the Completion; and (ii) immediately
upon the Completion are set out below:
Immediately before the Completion
Shareholders

Number of
issued Shares

Approximate
% of issued
share capital
of the
Company

Immediately upon the Completion
Number of issued
Shares

(%)Note 1

Approximate
% of issued
share capital of
the Company
(%)Note 1

GenScript
CorporationNote

799,999,123

36.31

799,999,123

35.08

Other
nonpublic
Shareholders
The Placees

4,016,989

0.18

4,016,989

0.18

-

-

77,126,000

3.38

Other
public
Shareholders

1,399,344,351

63.51

1,399,344,351

61.36

Total

2,203,360,463

100.00

2,280,486,463Note 3

100.00

2

Note:
1.

The aggregate of the percentage figures in the table above may not add up to the relevant subtotal or total percentage
figures shown due to rounding of the percentage figures to two decimal places.

2

2.

GenScript Corporation is a company incorporated in the State of Delaware in the U.S. and one of the controlling
shareholders of the Company. As at the date of this announcement, it was owned as to approximately 10.87%,
20.19%, 4.86%, 0.93%, 0.96%, 2.44%, 22.76%, 22.66%, 2.37%, 8.06%, 1.78%, 1.05%, and 1.07% by Frank Zhang,
the Zhang Trust, Weihong Jin, the Jin 2025 Trust, the Jin 2023 Trust, the Jin 2026 Trust, Larry Wang, Karen Wu (in
her own name and through certain family trustees), Sally Wang, the Wang Trust, the Wang 2026 Trust, Yingjun Mu
and Charity B-Community Foundation of New Jersey, respectively.

3.

Represents the total number of issued Shares immediately upon the Completion, assuming that no new Shares are
issued and allotted under the Company’s post-IPO share option scheme approved and adopted by written resolutions
of its then sole shareholder on 7 December 2015.

This announcement has been issued in the English language with a separate Chinese language translation. If
there is any inconsistency or ambiguity between the English version and the Chinese version, the English
version shall prevail.
By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director
Hong Kong, 15 September 2026
As at the date of this announcement, the executive Directors are Mr. Robin Meng, Dr. Frank Zhang, Dr. Li
Zhu and Ms. Sally Wang; and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Andy
Cheung, Mr. Ethan Pan, Dr. John Quelch, Dr. Ross Grossman and Dr. Victor Shi.

3

香港交易及結算所有限公司及香港聯合交易所有限公司(「聯交所」）對本公告的內容概不負責，
對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而
產生或因倚賴該等內容而引致的任何損失承擔任何責任。
本公告僅供參考，並不構成收購、購買或認購本公司證券的邀請或要約。
本公告及其任何副本概不得直接或間接在美國，或在刊發或派發本公告屬違法的任何其他司法
管轄區刊發或派發。本公告並不構成在美國購買或認購證券的任何要約或招攬，亦不構成其一
部份。
本公告所述證券並無亦不會根據《1933 年美國證券法》（經修訂）（「美國證券法」）登記，且除
非已根據美國證券法登記，或依照美國證券法獲豁免登記，或在無須根據美國證券法登記的交
易中，否則不得在美國發售或出售。本公司無意根據美國證券法登記本公告提及的任何證券，
也無意在美國進行證券公開發行。

Genscript Biotech Corporation
（於開曼群島註冊成立的有限公司）
（股份代號：1548）

根據一般授權配售新股份完成交割
聯席整體協調人及聯席配售代理

（按英文字母順序排序）

兹提述金斯瑞生物科技股份有限公司（「
「本公司」
）日期為 2026 年 9 月 11 日的公告，内容有關根據
一般授權配售新股份（「
「配售公告」）。除另有界定者外，本公告所用專有詞彙與該公告所界定者具
有相同涵義。
配售事項交割
董事會欣然宣佈，配售協議所載之所有條件均已獲得履行，並且交割已於 2026 年 9 月 15 日依照配
售協議的條款及條件完成。
合共 77,126,000 股配售股份（相當於緊接配售事項交割前本公司已發行股本約 3.50%以及緊隨配售
事項交割後經配發及發行配售股份擴大後本公司已發行股本的約 3.38%）已成功按每股 30.50 港元
的配售價配售予不少於六名承配人。
經董事作出一切合理查詢後所深知、盡悉及確信：各承配人及彼等最終實益擁有人（如適用）均為
獨立第三方。此外，据本公司所知，概無承配人及彼等最終實益擁有人因配售事項而成為本公司主
要股東（定義見上市規則）。

1

本公司來自配售事項的所得款項總額約為 2,352.3 百萬港元，扣除配售佣金及其他相關成本和費用
後，配售事項所得款項淨額約為 2,327.1 百萬港元。有關所得款項擬定用途之詳情，請參閱配售公
告。
如配售公告所披露，於交割後，本公司將依照包括中國證監會備案在內的相關適用法律及法規，向
中國監管機構進行備案。
配售事項對本公司持股結構的影響
本公司於(i)緊接交割前；及(ii)緊隨交割後的持股結構如下表：
緊接交割前
股東

已發行股份
數目

緊隨交割後

佔本公司已
發行股本的
概約百分比
(%)

已發行股份
數目

附註 1

佔本公司已
發行股本的
概約百分比
(%)

附註 1

GenScript
Corporation 附註 2
其他非公眾股東
承配人
其他公眾股東

799,999,123

36.31

799,999,123

35.08

4,016,989
1,399,344,351

0.18
63.51

4,016,989
77,126,000
1,399,344,351

0.18
3.38
61.36

合計

2,203,360,463

100.00

2,280,486,463 附註 3

100.00

附註：
1.

由於百分比數字四捨五入至小數點後兩位，上表中百分比數字的總和可能與所示的相關小計或總百分比
數字不符。

2.

GenScript Corporation 為一家於美國特拉華州註冊成立的公司，亦為本公司控股股東之一。於本公告日期，
其分別由章方良、章氏信託、金偉紅、金氏 2025 年信託、金氏 2023 年信託、金氏 2026 年信託、王魯泉、
吳詠梅（以其本人名義及通過若干家族信託持有）
、 王燁、王氏信託、王氏 2026 年信託、牟英軍及新澤
西州慈善 B 社區基金會分別擁有約 10.87%、 20.19%、 4.86%、0.93%、 0.96%、 2.44%、 22.76%、
22.66%、 2.37%、 8.06%、 1.78%、 1.05%及 1.07%。

3.

代表於交割時的已發行股份總數，並假設在本公司於 2015 年 12 月 7 日由當時唯一股東以書面決議批准及
採納的首次公開發售後股份期權計劃下，並無發行及配發任何新股份。

2

本公告以英文發佈，並附有中文翻譯。如中英文版本有任何不一致或歧義，應以英文版爲準。

承董事會命
Genscript Biotech Corporation

主席及執行董事
孟建革

香港，2026 年 9 月 15 日

於本公告日期，執行董事為孟建革先生、章方良博士、朱力博士及王燁女士；及獨立非執行董事為
Alphonse Galdes 博士、張耀樑先生、潘九安先生、John Quelch 博士、Ross Grossman 博士及施晨陽博士。

3